Abstract: Disclosed are a compound as an inhibitor of complement factor D, and a pharmaceutical composition thereof and the use thereof. Specifically disclosed are a compound as represented by formula (I), a tautomer thereof, a stereoisomer thereof and a prodrug thereof, or a pharmaceutically acceptable salt of any one of the above-mentioned compounds, or a solvate of any one of the above-mentioned compounds. The compound has a good inhibitory activity on complement factor D, and has an excellent pharmacokinetic and pharmacodynamic activity.

Abstract: A smooth cooperative lane change control method for multi-connected and autonomous vehicles (CAVs), including: acquiring vehicle information of a lane-changing vehicle M and four surrounding vehicles A, B, C and D; constructing uncontrolled-vehicle and controlled-vehicle motion state prediction models; according to the motion state prediction models, predicting motion states of the lane-changing vehicle M, and the vehicles A, B, C and D; constructing an upper-layer optimization model to calculate an optimal control value and an optimized motion state of the lane-changing vehicle M and an optimal control value of the vehicle A; constructing a lower-layer optimization model to calculate an optimal control value of the vehicle D; and controlling the lane-changing vehicle M, the vehicle A and the vehicle D to run according to a corresponding optimal control value.

Abstract: The present disclosure provides a substituted pyrazolo[1,5-a]pyridine compound, a composition including the same, and a use thereof. The substituted pyrazolo[1,5-a]pyridine compounds is a compound represented by formula (I) or the tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof. The compound of the present disclosure and composition thereof are useful for treating RET kinase-mediated diseases or conditions and have more excellent pharmacokinetic properties.

Abstract: A solid-state ion conductor including a compound of Formula 1: Li(3+2y1)B(P1?y1A1y1O4)2??Formula 1 wherein, in Formula 1, A1 is an element of Groups 4, 14, or a combination thereof, and has an oxidation state of +4, and 0<y1<1.

Abstract: A solid-state ion conductor including a compound of Formula 1: Li4?x?a?(b+2)yAxMa(SeO3)2?yXby??Formula 1 wherein, in Formula 1, A is an element of Groups 1 or 11, or a combination thereof, M is an element of Groups 2 to 17, or a combination thereof, wherein an oxidation state a of M is 2?a?7, X is a cluster anion having an oxidation state of b, wherein ?3?b??1, 0<(4?x?a?(b+2)y)?2, x?0, and 0?y?2.

Abstract: Provided are a substituted benzimidazole compound, and a composition comprising same and use thereof. The substituted benzimidazole compound is a compound represented by formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate or solvate compound, polymorph, stereoisomer, or isotopic variation thereof. The compound can be used for treating and/or preventing related diseases caused by MEK, such as hyperproliferative diseases, pancreatitis, kidney diseases, blastocyte implantation, and diseases related to vasculogenesis or angiogenesis.

Abstract: Disclosed are a heterocyclic compound, and an intermediate thereof, a preparation method therefor and the use thereof. Namely, provided are a heterocyclic compound as shown in formula I-a, and a tautomer and a pharmaceutically acceptable salt thereof, wherein the compound has a good water solubility and pharmacokinetic properties.

Abstract: Disclosed in the present invention are a pharmaceutical composition, a preparation, and a preparation method therefor and the use thereof. The pharmaceutical composition contains an active ingredient and a pharmaceutically acceptable excipient. The active ingredient contains a compound represented by formula A. The compound represented by formula A is selected from one, two or more of the crystal form I, the crystal form III and the crystal form V. The excipient is selected-from or comprises, but is not limited to, one, two or more of the following excipients: a diluent, a disintegrant, an adhesive, a glidant and a lubricant. The pharmaceutical composition and the preparation of the present invention have a good safety and/or stability, and a high P2X3 antagonistic activity, and have less effect on the taste.

Abstract: Provided are a compound as represented by formula (D) and a preparation method therefor, where X2 is a halogen, Pg is selected from H and an amino protecting group, such as Cbz, Boc, Fmoc, Alloc, Teoc, methoxycarbonyl or ethoxycarbonyl. Also provided are a synthesized intermediate compound of the formula (D) compound and a preparation method for the intermediate compound.

Abstract: A method for shale gas exploitation includes performing horizontal drilling operation on an area to be constructed, forming a crack around a horizontal drill hole wall by shaped charge perforation; expanding the crack around a horizontal hole hydraulic fracturing, and extracting methane gas after a fracturing fluid is discharged; after methane gas is reduced, performing in-situ combustion explosion fracturing on the methane involved in horizontal drilling; thereafter continuing to expand the crack in the horizontal drill hole such that methane continues to seep out, and continuing extracting methane; repeating combustion explosion fracturing and extraction operations, so as to increase combustion explosion cracking permeability, and greatly enhance the exploitation effect of shale gas. The method is suitable for fracturing reconstruction of unconventional oil and gas reservoirs such as shale gas reservoirs, coal seam gas reservoirs and tight sandstone gas reservoirs.

Abstract: The present invention provides a diarylpyrazole compound, a composition comprising same, and a use thereof. The diarylpyrazole compound refers to the compound represented by a formula (I) or a tautomer, a stereoisomer, a prodrug, a crystalline form, a pharmaceutically acceptable salt thereof, a hydrate, or a solvent compound. The compound and the composition of the present invention can be used for treating BRAF kinase mutant proliferative diseases and have better pharmacokinetic properties.

Abstract: A solid-state ion conductor including a compound of Formula 1: Li(3+2y1)B(P1-y1A1y1O4)2??Formula 1 wherein, in Formula 1, A1 is an element of Groups 4, 14, or a combination thereof, and has an oxidation state of +4, and 0<y1<1.

Abstract: An acid addition salt of a ROCK inhibitor, and a crystal form, a composition and the pharmaceutical use thereof are provided. The acid addition salt is an acid addition salt of compound A and any one of the following acids: hydrochloric acid, p-toluenesulfonic acid, benzenesulfonic acid, maleic acid, tartaric acid, oxalic acid, fumaric acid, sulfuric acid, methanesulfonic acid, phosphoric acid, succinic acid or citric acid (A). The acid addition salt of compound A and the crystal form thereof have the characteristics of high solubility, good stability, high purity, few impurities and high bioequivalence, and are beneficial for the storage, quality control and druggability of drugs.

Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.

Abstract: In some examples, an embolization device includes multiple sections with three-dimensional non-helical structures when deployed at a vascular site. The multiple sections include a first section and one or more second sections that are smaller than the first section. The first section may have a deployed structure configured to anchor the device at a vascular site (e.g., a blood vessel) of a patient while each of the one or more second sections may be formed from loops that configured to pack and obstruct the vascular site. In some cases, the embolization device also includes a third section having a deployed configuration with multiple helical windings or loops is configured to anchor the embolization device at the vascular site.

Abstract: The present application disclose a method and a device for detecting and correcting abnormal scoring of peer reviews, which includes: converting collected scoring data into a two-dimensional matrix and preprocessing the data; determining the anomaly of the processed structured data with a one-way anomaly detection method, a consistency check method and a two-way anomaly detection method, and classifying the detected abnormal data into an abnormal data set; repairing the abnormal data for the abnormal data set with an information entropy correction method; generating an ability evaluation report according to the abnormal data set, performing weighed averaging on the corrected scoring data according to the scoring weights of reviewers in the ability evaluation report to obtain a final scoring result, and generating an abnormal scoring correction report. The present application can effectively detect the abnormal phenomenon of peer reviews in the performance appraisal of enterprise personnel.

Abstract: The present application disclose a method and a device for detecting and correcting abnormal scoring of peer reviews, which includes: converting collected scoring data into a two-dimensional matrix and preprocessing the data; determining the anomaly of the processed structured data with a one-way anomaly detection method, a consistency check method and a two-way anomaly detection method, and classifying the detected abnormal data into an abnormal data set; repairing the abnormal data for the abnormal data set with an information entropy correction method; generating an ability evaluation report according to the abnormal data set, performing weighed averaging on the corrected scoring data according to the scoring weights of reviewers in the ability evaluation report to obtain a final scoring result, and generating an abnormal scoring correction report. The present application can effectively detect the abnormal phenomenon of peer reviews in the performance appraisal of enterprise personnel.

Abstract: A method for shale gas exploitation includes performing horizontal drilling operation on an area to be constructed, forming a crack around a horizontal drill hole wall by shaped charge perforation; expanding the crack around a horizontal hole hydraulic fracturing, and extracting methane gas after a fracturing fluid is discharged; after methane gas is reduced, performing in-situ combustion explosion fracturing on the methane involved in horizontal drilling; thereafter continuing to expand the crack in the horizontal drill hole such that methane continues to seep out, and continuing extracting methane; repeating combustion explosion fracturing and extraction operations, so as to increase combustion explosion cracking permeability, and greatly enhance the exploitation effect of shale gas. The method is suitable for fracturing reconstruction of unconventional oil and gas reservoirs such as shale gas reservoirs, coal seam gas reservoirs and tight sandstone gas reservoirs.

Abstract: In some examples, an embolization device includes multiple sections with three-dimensional non-helical structures when deployed at a vascular site. The multiple sections include a first section and one or more second sections that are smaller than the first section. The first section may have a deployed structure configured to anchor the device at a vascular site (e.g., a blood vessel) of a patient while each of the one or more second sections may be formed from loops that configured to pack and obstruct the vascular site. In some cases, the embolization device also includes a third section having a deployed configuration with multiple helical windings or loops is configured to anchor the embolization device at the vascular site.

Abstract: A system for providing a persona-driven and artificially-intelligent avatar is disclosed. The avatar may be utilized to represent an artificially-intelligent virtual assistant that may perform actions on behalf of a user, such as actions related to personal shopping for the user. Notably, the avatar may influence artificial intelligence algorithms supporting the functionality of the virtual assistant via quantifiable traits of a persona of the avatar. In particular, the quantifiable traits of the persona of the avatar may be utilized to range bound the controlling parameters of the algorithms such that the virtual assistant represented by the avatar performs actions that conform to the ranged-bounded controlling parameters. Metrics corresponding to the performance of the virtual assistant may be tracked, and the system may modify parameters of the virtual assistant based on the metrics so as to adjust future actions performed by the virtual assistant for the user.